Michael Severino will replace the company’s longtime leader Doug Ingram on Tuesday. Severino joins from Flagship’s gene editing biotech Tessera Therapeutics, where he had been CEO since 2022.
Sarepta Therapeutics has found its new CEO as it seeks to recover from a calamitous past year.
Michael Severino will replace the company’s longtime leader …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing…
The beleaguered Sarepta Therapeutics named Michael Severino, who previously led Tessera Therapeutics, as its new CEO.
Some five months after announcing the planned retirement of its longtime CEO Doug Ingram over what the helmsman dubbed an “ironic…
Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA…
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
Michel Detheux has succeeded Rita Balice-Gordon as CEO of Danish neuro biotech Muna Therapeutics.
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
Sarepta names Michael Severino, former Tessera CEO, as new chief executive
Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter
Biotech Innovator InstaMed® Pharmaceuticals Appoints Tracy Gibbs, PhD, as Chief Executive Officer Ahead of Worldwide Launch of Non-Injectable Peptide Platform
Secretome Therapeutics Expands Rare Disease Leadership Team
